Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial (S36.004)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To determine if non-myeloablative HSCT is superior to continuing DMD therapy.
Background: We previously reported that non-myeloablative HSCT can be performed safely and is accompanied by long-term improvement in neurological disability in patients with RRMS.
Design/Methods: Patients on stable DMDs with > 2 relapses within the prior 12 months were randomized (1:1) to treatment with cyclophosphamide and rabbit anti-thymocyte globulin followed by hematopoietic stem cell infusion or to a control arm with continued treatment with the most appropriate DMD as judged by their treating neurologist. The primary endpoint was treatment failure defined as an increase in EDSS, assessed by a blinded evaluating neurologist, by at least 1.0 point sustained for at least 6 months. Patients on DMDs who failed after at least 1 year of treatment were allowed to crossover to HSCT.
Results: 110 patients were randomized, 55 to each arm. Three HSCT patients were withdrawn: two for failing enrollment criteria, one for recurrent infections occurring before transplant. Five control patients were withdrawn after soliciting transplants at other centers. No deaths occurred and no CTC grade 4 non-hematopoietic toxicities occurred in the transplant arm. DMDs (number of patients) used in the control arm were: natalizumab (22), dimethyl fumerate (18), fingolimod (13) interferons (10), glatiramer acetate (8), and mitoxantrone (5). Other immune drugs used in the control arm were corticosteroids (39), cyclophosphamide (2) and rituximab (2). With a mean follow up of 3 years (range 1 to 5 years), treatment failure was 60% (30 of 50) for control arm and 6% (3 of 52) for HSCT (P < 0.001). During the first year after HSCT, mean EDSS improved from 3.5 to 2.4 while it worsened from 3.3 to 3.9 in the control arm (P<0.001).
Conclusions: HSCT for RRMS with > 2 relapses a year was superior to continued DMDs.
Disclosure: Dr. Burt has nothing to disclose. Dr. Balabanov has nothing to disclose. Dr. Snowden has nothing to disclose. Dr. Sharrack has nothing to disclose. Dr. Oliveira has nothing to disclose. Dr. Burman has nothing to disclose.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.